ISTA Pharmaceuticals, Inc. (ISTA) announced that it has received approval from the U.S. Food and Drug Administration or FDA for its supplemental New Drug Application or sNDA for BROMDAY.
Commenting on BROMDAY, the company stated that it is the only ophthalmic nonsteroidal anti-inflammatory drug or NSAID for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
ISTA added that it expects to launch BROMDAY prior to the end of 2010.
For comments and feedback: editorial@rttnews.com